List of SBIR/STTR awards granted to Aqualung Therapeutics
Aqualung TherapeuticsName | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A STTR Phase I contract was awarded to Aqualung Therapeutics in August, 2019 for $225,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 1R41HL147769-01 | Phase I | 225,000 | August 15, 2019 | |||||||
A STTR Phase I contract was awarded to Aqualung Therapeutics in June, 2020 for $300,001.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 1R42HL152888-01 | Phase I | 300,001 | June 1, 2020 | |||||||
A STTR Phase II contract was awarded to Aqualung Therapeutics in June, 2021 for $1,000,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 4R42HL152888-02 | Phase II | 1,000,000 | June 1, 2021 | |||||||
A STTR Phase I contract was awarded to Aqualung Therapeutics in September, 2022 for $259,613.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 1R42HL164300-01 | Phase I | 259,613 | September 1, 2022 | |||||||
A STTR Phase I contract was awarded to Aqualung Therapeutics in September, 2022 for $269,233.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 1R42DK135208-01 | Phase I | 269,233 | September 19, 2022 | |||||||
A STTR Phase I contract was awarded to Aqualung Therapeutics in September, 2020 for $265,096.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 1R41HD101202-01A1 | Phase I | 265,096 | September 18, 2020 | |||||||
A STTR Phase II contract was awarded to Aqualung Therapeutics in May, 2020 for $750,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 4R42HL145930-02 | Phase II | 750,000 | May 15, 2020 | |||||||
A STTR Phase I contract was awarded to Aqualung Therapeutics in September, 2022 for $259,613.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 1R41HL164154-01 | Phase I | 259,613 | September 23, 2022 | |||||||
A STTR Phase I contract was awarded to Aqualung Therapeutics in June, 2019 for $225,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 1R42HL145930-01 | Phase I | 225,000 | June 1, 2019 | |||||||
A STTR Phase I contract was awarded to Aqualung Therapeutics for $631,234.0 USD from the U.S. Department of Health & Human Services. | STTR | 1R41HL110707-01 | Phase I | 631,234 | ||||||||
A STTR Phase II contract was awarded to Aqualung Therapeutics in August, 2023 for $975,215.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 4R42DK135208-02 | Phase II | 975,215 | August 1, 2023 | |||||||
A SBIR Phase II contract was awarded to Aqualung Therapeutics in September, 2023 for $1,500,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44HL145930-04 | Phase II | 1,500,000 | September 10, 2023 | |||||||
A STTR Phase II contract was awarded to Aqualung Therapeutics in September, 2023 for $809,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | STTR | 4R42HL164300-02 | Phase II | 809,000 | September 19, 2023 |
